MHRA approves Wegovy for MASH with moderate-to-advanced liver fibrosis
Published · Updated
What happened
The MHRA authorised Wegovy for treatment of MASH in adults with moderate-to-advanced liver fibrosis, extending the medicine beyond obesity-related use into chronic liver disease. This is a discrete UK regulatory action taken within the past 24 hours.
Why it matters
This expands the clinical and commercial footprint of semaglutide into a major metabolic liver disease indication, likely influencing treatment guidelines, payer decisions, and supply planning in other markets. It also raises near-term questions about capacity, affordability, and evidence translation from regulatory approval into real-world care pathways.
On 3 July 2026, the UK Medicines and Healthcare products Regulatory Agency approved semaglutide (Wegovy) for adults with metabolic-associated steatohepatitis and moderate-to-advanced liver fibrosis. The decision creates a new licensed treatment option in a high-burden chronic liver disease area that has had limited pharmacological options. It has immediate implications for NHS commissioning, NICE appraisal pathways, prescribing criteria, and potential demand management for GLP-1 supply.
Watch for
NICE acknowledgement on or after 2026-07-04 of appraisal routing or interim position for semaglutide in MASH NHS England publication on or after 2026-07-04 of commissioning guidance, prescribing restrictions, or implementation advice for hepatology use Novo Nordisk statement on or after 2026-07-04 on UK supply allocation or manufacturing capacity for Wegovy following the new indication British Association for the Study of the Liver update on or after 2026-07-04 to treatment guidance or clinical positioning for semaglutide in MASH
Sources
Researched and written by AI from the sources listed, under published rules. How V³ Aware is made